MapMyGenome: Financial Breakdown
Decoding financial health metrics of MapMyGenome
Total Revenue₹31.2 Cr1%Prev. FY
Total Expenses₹29.5 Cr-26%Prev. FY
Profit After Tax₹1.8 Cr119%Prev. FY
Total Assets₹36.8 Cr24%Prev. FY
Net Profit Margin5.8%119%Prev. FY
FAQs on Financials of MapMyGenome
Yes. In FY25, MapMyGenome reported a profit after tax of ₹1.8 Cr, making it profitable.
MapMyGenome's revenue grew 1.9% year-on-year, from ₹30.6 Cr in FY24 to ₹31.2 Cr in FY25.
MapMyGenome's estimated EBITDA for FY25 was ₹4.8 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, MapMyGenome posted revenue of ₹31.2 Cr (up 1.9% YoY) and a profit after tax of ₹1.8 Cr. Explore the full financials of MapMyGenome here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links